Clinical trials: Extensive Disease Small Cell Lung Cancer
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Neoplasm, Small Cell Lung Cancer
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Small cell lung cancer is a highly malignant tumor, and its first-line treatment has not broken through platinum-containing dual-drug chemotherapy in the past 30 years.
- Conditions
- Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors
- Trial name
- NCT04490421
- Testing
- Camrelizumab combined with Apatinib, Etoposide and Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fuzhou General Hospital
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
This phase II trial studies how well hypofractionated radiation therapy after durvalumab and chemotherapy works to shrink tumors in patients with stage IV extensive stage small cell lung cancer.
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT05161533
- Testing
- Carboplatin, Cisplatin, Durvalumab
- Where
- United States
- Sponsor
- University of Washington
SCLC,Extensive Stage
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated…
- Trial name
- NCT05595460
- Testing
- RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- RayzeBio, Inc.
Lung Cancer
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004137
- Testing
- filgrastim, carboplatin, paclitaxel
- Where
- 85 sites in United States
- Volunteers
- 88 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003606
- Testing
- cisplatin, cyclophosphamide, epirubicin hydrochloride
- Where
- France
- Volunteers
- 216 people
- Sponsor
- UNICANCER
Lung Cancer
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in…
- Trial name
- NCT00660504
- Testing
- Amrubicin Hydrochloride, Etoposide-Cisplatin combined chemotherapy
- Where
- 15 sites in China
- Volunteers
- 300 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Small Cell Lung Cancer
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and…
- Trial name
- NCT02499770
- Testing
- Carboplatin, Trilaciclib, Etoposide
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 122 people
- Sponsor
- G1 Therapeutics, Inc.
Extensive Stage Lung Small Cell Carcinoma
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of LB-100 when given together with carboplatin, etoposide, and atezolizumab for the treatment of untreated extensive-stage small cell lung cancer.
- Trial name
- NCT04560972
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
This phase II trial studies how well carboplatin and etoposide with or without oblimersen sodium works in treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT00042978
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Small-cell Lung Cancer
PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study
prophylactic cranial irradiation （PCI）was verified to decrease the brain metastases rates and improve the overall survival（OS）for patients with limited stage small cell lung cancer.We hypothesis that patients with extensive-stage…
- Trial name
- NCT04535739
- Testing
- prophylactic cranial irradiation
- Where
- China
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
This phase II trial is studying how well giving UCN-01 together with topotecan works in treating patients with small cell lung cancer that relapsed or progressed after previous chemotherapy.
- Trial name
- NCT00098956
- Testing
- topotecan hydrochloride, 7-hydroxystaurosporine
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells. It is not yet known whether NTX-010 is more effective than a placebo in treating small cell lung cancer.
- Trial name
- NCT01017601
- Testing
- Seneca Valley virus-001
- Where
- 196 sites in United States
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Small Cell Lung Carcinoma
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
CC-90011-SCLC-001 is a multicenter, Phase 1b, open-label, dose finding study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently and sequentially to standard of care platinum-based…
- Trial name
- NCT03850067
- Testing
- CC-90011, Cisplatin, Carboplatin
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- Celgene
SCLC, Extensive Stage
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
This study hypothesizes that nanocrystalline megestrol acetate can improve the cachexia condition in patients and enhance the efficacy of immunochemotherapy regimens.
- Trial name
- NCT06793228
- Testing
- Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with…
- Trial name
- CANTABRICO (NCT04712903)
- Testing
- Durvalumab, Cisplatin, Etoposide
- Where
- 34 sites in Spain
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Extensive Small Cell Lung Cancer
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
This single-arm, open-label, Phase II study assesses first-line QL1706 + bevacizumab (anti-VEGF) + platinum/etoposide chemotherapy to treat naïve ES-SCLC patients.The main questions it aims to answer are: Evaluate efficacy and…
- Trial name
- QL1706 (NCT07083375)
- Testing
- QL1706 , bevacizumab, etoposide , cisplatin or carboplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zhijie Wang
Small Cell Lung Carcinoma
A Study of LY2940680 in Small Cell Lung Cancer
The purpose of this study is to find a recommended dose of LY2940680 that can be safely given in combination with etoposide and carboplatin followed by LY2940680 alone in participants with extensive-disease small cell lung…
- Trial name
- NCT01722292
- Testing
- LY2940680, Carboplatin, Etoposide
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Small-cell Lung Cancer
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
To compare the efficacy and safety between teniposide, cisplatin and serplulimab regimen and etoposide, cisplatin and serplulimab regimen in the treatment of extensive stage small lung cancer
- Trial name
- NCT07583511
- Testing
- Teniposide, Etoposide, serplulimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Small Cell Lung Cancer Extensive Stage
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
This is a prospective, single-arm clinical study designed to evaluate the 6-month progression-free survival rate (6-month PFS rate) of a PD-L1 inhibitor combined with apatinib as first-line maintenance treatment for…
- Trial name
- NCT06429696
- Testing
- PD-L1 inhibitor combined with apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University